Print

Purpose

The purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine. This study is seeking participants who: - are generally healthy and 7 years of age and older, - have already been vaccinated with 4 doses of VLA15 (from the VALOR study), and have blood sample taken post dose 4. - are not currently taking, or haven't recently taken, medicines like chemotherapy, blood products, or blood thinners. - are not pregnant or breastfeeding and do not plan to become pregnant while receiving the study vaccine. All participants in this study will receive a total of 1 dose through a shot in the upper arm, either VLA15 or saline shot (saltwater). The study will compare the experiences of people receiving the study vaccine or saltwater shot. Participants will take part in this study for about 12 months. During this time, they will have 4 planned clinic visits. The clinic visits may include having a health check, giving a small amount of blood and getting the study vaccine or saltwater as a shot at the first visit.

Condition

Eligibility

Eligible Ages
Over 7 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Participants who are healthy as determined by medical history and clinical judgment. - Participants willing and able to comply with all scheduled visits, IP receipt, and other procedures throughout the study. - Able to provide Informed Consent. - Participants must have received 4 doses of VLA15 in the C4601003 study, and have a V7 blood sample available.

Exclusion Criteria

  • Pregnant or breastfeeding participants. - Allergies or contraindications to vaccines or their components. - Health issues including: blood clotting deficiencies, immunodeficiencies, bone marrow disorder, or uncontrolled psychiatric conditions. - Receipt of therapies to treat malignancies, blood/plasma products and immunoglobulins, systemic corticosteroids and immunosuppressants, or anticoagulant therapy in recent medical history. - Recent or concurrent participation in a separate interventional study. - Staff or direct family of the study site staff and Sponsor.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Prevention
Masking
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description
Third-party blind unblinded

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
VLA15-1A 		Participants will receive a single injection in the muscle (IM) of VLA15 at Visits 1, two years after their 4th dose of VLA15
  • Biological: VLA15
    VLA15 injection IM
Placebo Comparator
VLA15-1B 		Participants will receive a single injection in the muscle (IM) of Saline at Visits 1, two years after their 4th dose of VLA15
  • Biological: Placebo
    Saline Injection
Experimental
VLA15-2A 		Participants will receive a single injection in the muscle (IM) of VLA15 at Visits 1, one year after their 4th dose of VLA15
  • Biological: VLA15
    VLA15 injection IM
Placebo Comparator
VLA15-2B 		Participants will receive a single injection in the muscle (IM) of saline at Visits 1, one year after their 4th dose of VLA15
  • Biological: Placebo
    Saline Injection

Recruiting Locations

University of Massachusetts Chan Medical School
Worcester, Massachusetts 01655

Smith Allergy and Asthma Specialists
Cortland, New York 13045

Smith Allergy & Asthma Specialists
Horseheads, New York 14845

Altoona Center For Clinical Research
Duncansville, Pennsylvania 16635

Allegheny Health and Wellness Pavilion
Erie, Pennsylvania 16506

Central Erie Primary Care
Erie, Pennsylvania 16508

Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)
Pittsburgh, Pennsylvania 15236

Robert Packer Hospital
Sayre, Pennsylvania 18840

Frontier Clinical Research, LLC
Scottdale, Pennsylvania 15683

Northeast Clinical Trials Group
Scranton, Pennsylvania 18510

Frontier Clinical Research, LLC
Smithfield, Pennsylvania 15478

More Details

Status
Recruiting
Sponsor
Pfizer

Study Contact

Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com

Detailed Description

A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine, VLA15, in Healthy Participants ≥7 Years of Age Participants will be randomized in a 5:1 ratio to receive either one dose of VLA15 or placebo (saline) at the first visit. This study will use an external data monitoring committee (EDMC). The EDMC is independent of the Pfizer study team and includes only external members. The EDMC charter describes the role of the EDMC in more detail. Approximately 1712 participants will be enrolled in the study. Healthy individuals 7 years of age and older who have received 4 prior doses of active VLA15 from the C4601003 study, have a blood sample taken post dose 4, are willing to comply with all study procedures, and provide signed informed consent will be enrolled. Pregnant or breastfeeding individuals and fertile individuals who are unwilling or unable to use effective contraceptive methods as outlined in this protocol will not be enrolled. Individuals who have contraindication to vaccination, conditions or treatments that can inhibit the ability to mount an immune response to a vaccine, or other conditions that may increase the risk of study participation will be excluded from this study.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.